

Synthesis, Characterization and Antimicrobial Evaluation of New 5-Acetamido-3-acetyl-1,3,4-oxadiazoline Derivatives

Hany M. Dalloul^{1*} and Kholoud Abu Yunis²

¹Department of Chemistry, Faculty of Applied Sciences, Al-Aqsa University of Gaza, Palestine

²Ministry of Education of Gaza, 76888 Gaza Strip, Palestine

* **Corresponding author:** Prof. Hany M. Dalloul, Department of Chemistry, Faculty of Applied Sciences, Al-Aqsa University of Gaza, P.O. Box 4051, Gaza, 76888 Gaza Strip, Palestine, Email: hanydalool@gmail.com

Received date: August-26-2023, Manuscript No. tsoc-23-111366; **Editor assigned:** August-28 -2023, Pre-QC No. tsoc-23-111366(PQ);

Reviewed: September-12-2023, QC No tsoc-23-111366(Q); **Revised:** September-15-2023, Manuscript No. tsoc-23-111366(R);

Published: September-20- 2023, DOI.10.37532/0974-7516.2023.17(5).1-9

Abstract

A new series of 5-acetamido-3-acetyl-1,3,4-oxadiazoline derivatives were synthesized via oxidative cyclization reaction of different N-carbamoylhydrazones with acetic anhydride. The structures of obtained compounds were confirmed by IR, MS, ¹H NMR, ¹³C NMR and Elemental analysis methods and are in full agreement with their molecular structure. The synthesized 1,3,4-oxadiazolines were screened for in vitro for their biological activity against a variety of bacterial strains (*Enterococci*, *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella spp*, *Proteus spp*), and fungi (*Aspergillus niger*, *Candida albicans*), employing the nutrient agar disc diffusion method. The obtained results showed that these compounds have good inhibition against the tested pathogens.

Keywords: *N-acetyl-1,3,4-oxadiazolines; N-carbamoylhydrazones; Biological activity; Oxidative cyclization*

Introduction

Nitrogen containing heterocycles play an important role in the drug discovery process. The nitrogenated frames commonly formed as fractions in the structure of most drugs with various ring sizes; aromatic and nonaromatic rings; fused and bicyclic rings. Nitrogen heterocyclic medications are present in all therapeutic areas including cardiovascular and metabolic illnesses, Central Nervous System (CNS) disorders, anti-inflammatory, antineoplastic, anti-infective drugs, and among others. In drug discovery and development, oxadiazole rings are commonly employed as bioisosteric replacement for carbonyl-containing groups such as esters, amides, carbamates and hydroxamic esters. Such groups are usually unstable in 2 biological media, which poses as hurdle for their use in the structure of drug candidates. Over the last years, bioactive molecules containing the oxadiazole ring have been increasingly discovered, developed and studied. Moreover, the oxadiazole chemistry has been developed extensively and is still developing continuously. Presently it is possible to find the oxadiazole moiety in various compounds possess bioactivities as antitumor, antitubercular, anticonvulsant, antioxidant, antibacterial, antiviral, anti-inflammatory, insecticidal, antiparasitic agents, and cardioprotective agents [1-3].

Since 1950 a diversified reactions, various precursors are used to obtain an oxadiazoles having novel pharmacological activity [4]. Among them the substituted-1,3,4-oxadiazole derivatives have attracted considerable attention owing to their effective biological activity and extensive use in medication industries [5,6]. There are many reviews of the literature available on the correlation between the chemical structure and the biological activity of 1,3,4-oxadiazole derivatives [7]. Typically, several oxidizing agents were used to create 1,3,4-oxadiazole derivatives from acylhydrazones, as Lead Tetraacetate (LTA) in CH₂Cl₂, Phenyliodine (III) Diacetate (PIDA) in ethanol, electrolytic oxidation in methanolic sodium acetate (AcONa/CH₃OH) involving intramolecular cyclization to give 2-methoxy-1,3,4-oxadiazoline [3,8-12]. Recently Ultrasound-assisted synthesis of 2-amino-1,3,4-oxadiazoles through NBS-mediated oxidative cyclization of semicarbazones has been reported [13].

Using acid anhydride was the most common procedure of cyclization of acylhydrazones. The Acetic Anhydride (AA) is frequently

used as dehydrant in these kinds of reactions in many literatures. The treatment of acylhydrazones with acetic anhydride found to give 3-acetyl-2,5-disubstituted-1,3,4-oxadiazolines with good yield [14-18]. Therefore, as a part of our program focused on 1,3,4-oxadiazole with biological activity, and in connection with our interest in the chemistry of 1,3,4-oxadiazole. We outlined in the present research, the synthesis of some novel 3-cetyl-5-acetamido-1,3,4-oxadiazolines and their antimicrobial activity were investigated.

Experimental

Chemicals and instrumentations

All chemicals and reagents used in this research were purchased from Sigma-Aldrich (Germany), Merck Co. (Germany), Fluka Chemie Company (Switzerland) and Acros company (Belgium), and used without further purification (unless otherwise stated) where the manufacturer declared their class of purity. The purity of the obtained compounds was assessed by means of Thin Layer Chromatography (TLC) on plates of silica gel (60 F-254) supplied by 3 Merck Co. The melting points of the obtained compounds were determined on open capillary tube using a Stuart melting point apparatus (England) equipped with a thermometer and presented without any correction. The IR spectra were recorded on a Nicolet 6700 spectrometer (Thermo Scientific, Madison, WI, USA); in cm^{-1} .

The ^1H NMR spectra were recorded in (DMSO- d_6) at 300 MHz and ^{13}C NMR spectra at 75 MHz on a Bruker AM 300 NMR spectrometer. Chemical shift (δ) values are donated in ppm relative to Tetramethylsilane (TMS) as internal standard. The splitting patterns for NMR spectra are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) or combinations thereof. Coupling constants (J) are designated in Hz. Electron impact mass spectra were run on Finnegan MAT 8200 and 8400 Mass spectrometers at 70 eV. The elemental analysis was carried out at Microanalysis center of Cairo University, Giza, Egypt, and the obtained compounds analyzed satisfactorily for C, H and N and the results were within $\pm 0.3\%$ - 0.4% of the theoretical values.

Synthesis

General procedure for synthesis of carbamoyl hydrazones 3a-s: A mixture of semicarbazide hydrochloride 1 (15 mmol), aldehydes or ketones 2a-s (15 mmol), sodium acetate (15 mmol) and few drops of glacial acetic acid in methanol (30 mL) was stirred under reflux until reaction had completed (1 hr-2 hrs.). The reaction mixture was allowed to cool to room temperature, and the solid precipitate was filtered and recrystallized from ethanol or methanol to give the desired semicarbazones 3a-s in 85%-95% yield [13,19,20].

General procedure for synthesis of 1,3,4-oxadiazolines 4a-s: A mixture of carbamoyl hydrazones 3a-s (15 mmol-20 mmol) and excessive acetic anhydride (15 mL-25 mL) was stirred under reflux in oil bath for 2 hrs-3 hrs. After the reaction was completed (controlled by TLC), the reaction mixture was allowed to cool and the formed precipitate was collected and washed with potassium carbonate solution (10%) followed by water and dried. In some cases, where the precipitate not formed on cooling, the reaction mixture left for 2-3 days to vaporize the excess anhydride or removed *in vacuo*, and the residue washed with potassium bicarbonate solution (10%) and finally with water and dried. In all cases the resulting crude solid product was recrystallized from ethanol or ethyl acetate and air-dried to afford 1,3,4-oxadiazolines 4a-s.

5-Acetamido-3-acetyl-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4a): White solid (78% yield), m.p. 182°C-184°C. FTIR (KBr, cm^{-1}): 3267 (NH), 1675, 1670 (2C=O), 1610 (C=N), 1159 (C-OC). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 1.62 (d, J = 5.0 Hz, 3H, CH_3 of C_2 -oxad.), 2.32, 2.35 4 (s, 6H, 2 CH_3), 6.33 (q, J = 5.4 Hz, 1H, CH of C_2 -oxad.), 11.35 (s, 1H, NH). ^{13}C NMR (DMSO d_6 , 75 MHz): δ = 23.6, 23.3 (2 CH_3), 24.6 (CH_3), 91.6 (C_2 -oxad.), 150.3 (C=N, oxadiazole ring), 167.2, 166.9 (2C=O). MS: m/z 185 [M^+]; Anal. Cald. for $\text{C}_7\text{H}_{11}\text{N}_3\text{O}_3$: C, 45.40; H, 5.99; N, 22.69%. Found; C, 45.18; H 6.16; N, 22.51%.

5-Acetamido-3-acetyl-2-ethyl-2,3-dihydro-1,3,4-oxadiazole (4b): White solid (75% yield), m.p. 169°C -172°C. FTIR (KBr, cm^{-1}): 3269 (NH), 1676, 1668 (2C=O), 1608 (C=N), 1163 (C-OC). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 1.05-1.11 (t, J = 7.0 Hz, 3H, CH_3 ethyl), 1.60-1.63 (m, 2H, CH_2 ethyl), 2.31-2.35 (s, 6H, 2 CH_3), 6.28 (t, J = 6.0 Hz, 1H, CH at C_2 -oxad.), 11.33 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 100 MHz): δ = 13.3 (CH_3 ethyl), 18.7 (CH_2 ethyl), 23.5, 23.3 (2 CH_3), 92.5 (C_2 -oxad.), 149.6 (C=N, oxad.), 166.9, 167.4 (2C=O). MS: m/z 199 [M^+]; Anal. Cald. for $\text{C}_8\text{H}_{13}\text{N}_3\text{O}_3$: C, 48.23; H, 6.58; N, 21.09%. Found; C, 48.42; H 6.41; N, 20.92%.

5-Acetamido-3-acetyl-2-n-propyl-2,3-dihydro-1,3,4-oxadiazole (4c): White solid (77% yield), m.p. 176°C-178°C. FTIR (KBr, cm^{-1}): 3258 (NH), 1669, 1664 (2C=O), 1605 (C=N), 1160 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 0.95-1.01 (t, 3H, CH_3), 1.58-1.66 (m, 2H, CH_2), 2.00-2.26 (t, 2H, CH_2), 2.33-2.36 (s, 6H, 2 CH_3), 6.30 (t, J = 6.0 Hz, 1H, CH at C_2 -oxad.), 11.25 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 13.0 (CH_3), 16.9 (CH_2), 18.8 (CH_2), 23.5, 23.3 (2 CH_3), 92.7 (C_2 -oxad.), 149.6 (C=N, oxad.), 166.9/166.4 (2C=O). MS: m/z 213 [M^+]; Anal. Cald. for $\text{C}_9\text{H}_{15}\text{N}_3\text{O}_3$: C, 50.69; H, 7.09; N, 19.71%. Found; C, 50.91; H 6.91; N, 19.56%.

5-Acetamido-3-acetyl-2-n-hexyl-2,3-dihydro-1,3,4-oxadiazole (4d): White solid (73% yield), m.p. 187°C-189°C. FTIR (KBr, cm^{-1}): 3272 (NH), 1670, 1665 (2C=O), 1610 (C=N), 1154 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 0.65 (t, J = 6.0 Hz, 3H, hexyl group), 1.56-1.08 (m, 8H, 4CH₂, hexyl protons), 1.86 (q, J = 6.0 Hz, 2H, hexyl group), 2.30-2.33 (s, 6H, 2CH₃), 6.36 (t, J = 6.0 Hz, 1H, CH at C₂-oxad.), 11.26 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 100 MHz): δ = 23.7 (2CH₃), 26.7, 24.6, 19.6, 13.8, 11.7 (5CH₂), 7.6 (CH₃) (6 hexyl carbons), 92.4 (C₂-oxad.), 149.7 (C=N, oxad.), 166.8, 166.4 (2C=O). MS: m/z 255 [M⁺]; Anal. Cald. for C₁₂H₂₁N₃O₃: C, 56.45; H, 8.29; N, 16.46%. Found; C, 56.75; H 8.44; N, 16.63%.

5-Acetamido-3-acetyl-2-cyclohexyl-2,3-dihydro-1,3,4-oxadiazole (4e): White solid (75% yield), m.p. 193°C -195°C. FTIR (KBr, cm^{-1}): 3264 (NH), 1670, 1666 (2C=O), 1611 (C=N), 1152 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 1.96-1.20 (m, 11H, cyclohexyl protons), 2.30-2.33 (s, 6H, 2CH₃), 6.35 (d, J = 6.0 Hz, 1H, CH at C₂-oxad.), 11.32 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 23.7 (2CH₃), 40.3 (CH), 27.6 (2CH₂), 25.3 (2CH₂), 24.2 (CH₂) (cyclohexyl carbons), 92.6 (C₂-oxad.), 146.9 (C=N, oxad.), 166.9, 167.2 (2C=O). MS: m/z 253 [M⁺]; Anal. Cald. for C₁₂H₁₉N₃O₃: C, 56.90; H, 7.56; N, 16.59%. Found; C, 56.63; H 7.73; N, 16.42%.

5-Acetamido-3-acetyl-2-phenyl-2,3-dihydro-1,3,4-oxadiazole (4f): White solid (68% yield), m.p. 179°C-181°C. FTIR (KBr, cm^{-1}): 3258 (NH), 3033 (Ar-H), 1676, 1667 (2C=O), 1598 (C=N), 1162 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 2.30-2.33 (s, 6H, 2CH₃), 7.04 (s, 1H, CH at C₂-oxad.), 7.34-7.93 (m, 5H, arom.), 11.09 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 23.7 (2CH₃), 89.3 (C₂-oxad.), 134.2, 130.8, 128.7, 127.0, 126.7, 122.3 (6 arom. C), 149.8 (C=N, oxad.), 166.9, 167.3 (2C=O). MS: m/z 247 [M⁺]; Anal. Cald. for C₁₂H₁₃N₃O₃: C, 58.29; H, 5.30; N, 16.99%. Found; C, 58.60; H 5.46; N, 17.16%.

5-Acetamido-3-acetyl-2-(4-chlorophenyl)-2,3-dihydro-1,3,4-oxadiazole (4g): Yellow solid (70% yield), m.p. 166°C-169°C. FTIR (KBr, cm^{-1}): 3262 (NH), 2929, 2840 (Ar-H), 1678, 1668 (2C=O), 1604 (C=N), 1162 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 2.31-2.35 (s, 6H, 2CH₃), 7.08 (s, 1H, CH at C₂-oxad.), 7.34-7.93 (m, 4H, arom.), 11.04 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 23.4 (2CH₃), 89.7 (C₂-oxad.), 133.2, 131.2, 128.1, 125.7, 123.3, 119.2 (6 arom. C), 150.3 (C=N, oxad.), 166.8, 167.2 (2C=O). MS: m/z 281/283 [M⁺]; Anal. Cald. for C₁₂H₁₂ClN₃O₃: C, 51.17; H, 4.29; N, 14.92%. Found; C, 50.89; H 4.46; N, 14.74%.

5-Acetamido-3-acetyl-2-(2-furyl)-2,3-dihydro-1,3,4-oxadiazole (4h): White solid (72% yield), m.p. 167°C-169°C. FTIR (KBr, cm^{-1}): 3273 (NH), 2943 (Ar-H), 1667, 1657 (2C=O), 1593 (C=N), 1157 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 2.30-2.33 (s, 6H, 2CH₃), 7.90 (dd, J = 1.8 Hz, 1H furan ring), 7.71 (dd, J = 3.5 Hz, 1H furan ring), 7.56 (d, J = 3.5 Hz, 1H furan ring), 7.03 (s, 1H, CH at C₂-oxad.), 11.05 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 100 MHz): δ = 23.2, 23.4 (2CH₃), 88.6 (C₂-oxad.), 133.7, 131.5, 128.4, 127.2 (4 arom. C), 153.9 (C=N, oxad.), 166.4, 166.9 (2C=O). MS: m/z 237 [M⁺]; Anal. Cald. for C₁₀H₁₁N₃O₄: C, 50.63; H, 4.67; N, 17.71%. Found; C, 50.91; H 4.52; N, 17.58%.

5-Acetamido-3-acetyl-2-(2-thienyl)-2,3-dihydro-1,3,4-oxadiazole (4i): Light yellow (65% yield), m.p. 206°C-208°C. FTIR (KBr, cm^{-1}): 3257 (NH), 2953 (Ar-H), 1669, 1658 (2C=O), 1602 (C=N), 1159 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 2.33-2.38 (s, 6H, 2CH₃), 7.82 (d, J = 1.3 Hz, 1H thiophene ring), 7.72 (d, J = 3.4 Hz, 1H thiophene ring), 7.64 (d, J = 3.4 Hz, 1H thiophene ring), 7.07 (s, 1H, CH at C₂-oxad.), 11.02 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 23.3, 23.5 (2CH₃), 87.9 (C₂-oxad.), 130.8, 129.9, 128.2, 125.3 (4 arom. C), 147.9 (C=N, oxad.), 166.3, 167.0 (2C=O). MS: m/z 253 [M⁺]; Anal. Cald. for C₁₀H₁₁N₃O₃S: C, 47.42; H, 4.38; N, 16.59%. Found; C, 47.16; H 4.56; N, 16.76%.

5-Acetamido-3-acetyl-2,2-dimethyl-2,3-dihydro-1,3,4-oxadiazole (4j): Pale brown solid (86% yield), m.p. 198°C-201°C. FTIR (KBr, cm^{-1}): 3253 (NH), 1668, 1659 (2C=O), 1605 (C=N), 1165 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 1.53-1.56 (s, 6H, 2CH₃ of C₂ oxad.), 2.26- 2.36 (s, 6H, 2CH₃), 10.97 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 23.3, 23.6 (2CH₃), 6 24.3, 24.4 (2CH₃ at C₂-oxad.), 90.2 (quaternary C₂-oxad.), 147.6 (C=N, oxad.), 168.4, 169.9 (2C=O). MS: m/z 199 [M⁺]; Anal. Cald. for C₈H₁₃N₃O₃: C, 48.23; H, 6.58; N, 21.09%. Found; C, 48.50; H 6.39; N, 20.91%.

5-Acetamido-3-acetyl-2-ethyl-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4k): White solid (82% yield), m.p. 178°C-180°C. FTIR (KBr, cm^{-1}): 3268 (NH), 1673, 1668 (2C=O), 1601 (C=N), 1156 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 1.04 (t, J = 7.5 Hz, 3H, CH₃ of ethyl), 1.64 (q, 2H, CH₂ of ethyl), 2.13 (s, 3H, CH₃ of C₂ oxad.), 2.33-2.38 (s, 6H, 2CH₃), 10.98 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 9.6 (CH₃), 22.5 (CH₂), 23.3, 23.6 (2COCH₃), 24.6 (CH₃ at C₂-oxad.), 83.5 (C₂-oxad.), 154.5 (C=N, oxad.), 166.5, 167.6 (2C=O). MS: m/z 213 [M⁺]; Anal. Cald. for C₉H₁₅N₃O₃: C, 50.69; H, 7.09; N, 19.71%. Found; C, 50.38; H 7.30; N, 19.92%.

5-Acetamido-3-acetyl-2-cyclopropyl-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4l): Offwhite solid (76% yield), m.p. 217°C-219°C. FTIR (KBr, cm^{-1}): 3274 (NH), 1672, 1667 (2C=O), 1597 (C=N), 1249 (C-O-C). ^1H NMR (DMSO- d_6 , 300 MHz): δ = 0.55-0.67 (m, 4H, 2CH₂ of cyclopropyl), 1.26-1.32 (m, 1H, CH of cyclopropyl), 1.64 (s, 3H, CH₃ of C₂ oxad.), 2.38 (s, 6H, 2CH₃), 11.12 (s, 1H, NH). ^{13}C NMR (DMSO- d_6 , 75 MHz): δ = 3.1, 3.2 (2CH₂ cyclopropyl), 9.9 (CH cyclopropyl), 23.2, 23.5 (2COCH₃), 24.3 (CH₃ at C₂-

oxad.), 83.4 (C₂-oxad.), 154.2 (C=N, oxad.), 166.8, 167.3 (2C=O). MS: m/z 225 [M⁺]; Anal. Cald. for C₁₀H₁₅N₃O₃: C, 53.32; H, 6.71; N, 18.65%. Found; C, 53.59; H 6.52; N, 18.83%.

5-Acetamido-3-acetyl-2-methyl-2-phenyl-2,3-dihydro-1,3,4-oxadiazole (4m): White solid (72% yield), m.p. 196°C-198°C. FTIR (KBr, cm⁻¹): 3258 (NH), 3033, 2840 (Ar-H), 1656, 1648 (2C=O), 1611 (C=N), 1159 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 1.54 (s, 3H, CH₃ of C₂ oxad.), 2.27-2.33 (s, 6H, 2CH₃), 7.34-7.93 (m, 4H, arom.), 11.04 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 75 MHz): δ = 23.4 (2CH₃), 24.3 (CH₃ at C₂-oxad.), 89.7 (C₂-oxad.), 133.2, 131.2, 128.1, 127.6, 125.7, 121.6 (6 arom. C), 151.3 (C=N, oxad.), 166.8, 167.2 (2C=O). MS: m/z 261 [M⁺]; Anal. Cald. for C₁₃H₁₅N₃O₃: C, 59.76; H, 5.79; N, 16.08%. Found; C, 59.51; H 5.61; N, 15.91%

5-Acetamido-3-acetyl-2-(4-bromophenyl)-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4n): Light yellow solid (80% yield), m.p. 180°C-182°C. FTIR (KBr, cm⁻¹): 3257 (NH), 2923, 2833 (Ar-H), 1660, 1652 (2C=O), 1597 (C=N), 1149 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 1.51 (s, 3H, CH₃ of C₂ oxad.), 2.27-2.33 (s, 6H, 2CH₃), 7.56 (d, J = 4.2 Hz, 2H arom.), 7.34 (d, J = 2.1 Hz, 2H arom.), 11.00 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 75 MHz): δ = 23.6 (2CH₃), 24.6 (CH₃ at C₂-oxad.), 83.7 (C₂-oxad.), 133.7, 130.9, 128.5, 126.9, 123.7, 114.6 (6 arom. C), 7 149.9 (C=N, oxad.), 166.5, 167.6 (2C=O). MS: m/z 340/342 [M⁺]; Anal. Cald. for C₁₃H₁₄BrN₃O₃: C, 45.90; H, 4.15; N, 12.35%. Found; C, 46.18; H 4.33; N, 12.54%.

5-Acetamido-3-acetyl-2-(4-chlorophenyl)-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4o): Pale yellow solid (68% isolated yield), m.p. 207°C-210°C. FTIR (KBr, cm⁻¹): 3253 (NH), 2925, 2841 (Ar-H), 1676, 1667 (2C=O), 1611 (C=N), 1160 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 1.51 (s, 3H, CH₃ of C₂ oxad.), 2.28-2.35 (s, 6H, 2CH₃), 7.41 (d, J = 4.1 Hz, 2H arom.), 7.31 (d, J = 2.0 Hz, 2H arom.), 11.02 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 75 MHz): δ = 23.6 (2CH₃), 24.6 (CH₃ at C₂-oxad.), 83.8 (C₂-oxad.), 130.7, 128.9, 127.6, 123.5, 122.9, 118.7 (6 arom. C), 150.5 (C=N, oxad.), 166.7, 167.2 (2C=O). MS: m/z 295/297 [M⁺]; Anal. Cald. for C₁₃H₁₄ClN₃O₃: C, 52.80; H, 4.77; N, 14.21%. Found; C, 52.52; H 4.96; N, 14.01%.

5-Acetamido-3-acetyl-2-(2-furyl)-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4p): Off-White solid (73% isolated yield), m.p. 175°C-177°C. FTIR (KBr, cm⁻¹): 3272 (NH), 2939 (Ar-H), 1672, 1665 (2C=O), 1613 (C=N), 1158 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 1.54 (s, 3H, CH₃ of C₂ oxad.), 2.26-2.32 (s, 6H, 2CH₃), 7.97 (dd, J=1.8 Hz, 1H furan ring), 7.69 (dd, J = 3.5 Hz, 1H furan ring), 7.54 (d, J = 3.5 Hz, 1H furan ring), 11.06 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 75 MHz): δ = 23.4 (2CH₃), 24.3 (CH₃ at C₂-oxad.), 90.4 (C₂-oxad.), 130.3, 129.8, 128.2, 124.8 (4 C furan ring), 154.6 (C=N, oxad.), 167.0, 167.3 (2C=O). MS: m/z 251 [M⁺]; Anal. Cald. for C₁₁H₁₃N₃O₄: C, 52.59; H, 5.22; N, 16.72%. Found; C, 52.87; H, 5.41; N, 16.53%.

5-Acetamido-3-acetyl-2-(2-thienyl)-2-methyl-2,3-dihydro-1,3,4-oxadiazole (4q): White solid (74% isolated yield), m.p. 164°C-166°C. FTIR (KBr, cm⁻¹): 3257 (NH), 2945 (Ar-H), 1673, 1667 (2C=O), 1609 (C=N), 1162 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 1.52 (s, 3H, CH₃ of C₂ oxad.), 2.24-2.30 (s, 6H, 2CH₃), 7.92 (d, J = 1.3 Hz, 1H thiophene ring), 7.68 (d, J = 3.4 Hz, 1H thiophene ring), 7.48 (d, J = 3.4 Hz, 1H thiophene ring), 11.12 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 100 MHz): δ = 23.6 (2CH₃), 24.4 (CH₃ at C₂-oxad.), 90.6 (C₂-oxad.), 131.8, 128.9, 127.0, 125.3 (4 arom. C), 153.9 (C=N, oxad.), 167.1, 167.3 (2C=O). MS: m/z 267 [M⁺]; Anal. Cald. for C₁₁H₁₃N₃O₃S: C, 49.43; H, 4.90; N, 15.72%. Found; C, 49.71; H 4.09; N, 15.53%.

5-Acetamido-3-acetyl-2,2-dicyclopropyl-2,3-dihydro-1,3,4-oxadiazole (4r): White solid (66% isolated yield), m.p. 243°C dec. FTIR (KBr, cm⁻¹): 3255 (NH), 1672, 1660 (2C=O), 1612 (C=N), 1161 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 0.60-0.75 (m, 8H, 4CH₂ of cyclopropyl), 1.29-1.34 (m, 2H, 2CH of cyclopropyl), 2.22-2.29 (s, 6H, 2CH₃), 11.02 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 75 MHz): δ = 3.1, 3.2 (4CH₂ cyclopropyl), 9.6, 10.0 (2CH cyclopropyl), 23.4, 23.6 (2COCH₃), 83.7 (C₂-oxad.), 147.3 (C=N, oxad.), 166.9, 167.1 (C=O). MS: m/z 251 [M⁺]; Anal. Cald. for C₁₂H₁₇N₃O₃: C, 57.36; H, 6.82; N, 16.72%. Found; C, 57.05; H 6.62; N, 16.91%.

5-Acetamido-3-acetyl-2-methyl-2-(2-naphthyl)-2,3-dihydro-1,3,4-oxadiazole (4s): Pale solid (71% isolated yield), m.p. 217°C-220°C. FTIR (KBr, cm⁻¹): 3253 (NH), 3049, 2843 (ArH), 1659, 1648 (2C=O), 1610 (C=N), 1159 (C-O-C). ¹H NMR (DMSO-d₆, 300 MHz): δ = 1.60 (s, 3H, CH₃ of C₂ oxad.), 2.29-2.33 (s, 6H, 2CH₃), 7.36-8.45 (m, 7H, arom.), 11.06 (s, 1H, NH). ¹³C NMR (DMSO-d₆, 75 MHz): δ = 22.9 (2CH₃), 23.6 (CH₃ at C₂-oxad.), 84.3 (C₂-oxad.), 134.9, 132.6, 131.0, 129.5, 128.1, 127.6, 126.9, 126.2, 125.2, 121.5 (10 arom. C), 146.9 (C=N, oxad.), 166.6, 166.9 (2C=O). MS: m/z 311 [M⁺]; Anal. Cald. for C₁₇H₁₇N₃O₃: C, 65.58; H, 5.50; N, 13.50%. Found; C, 65.29; H 5.69; N, 13.32%.

Antimicrobial evaluation

In vitro antimicrobial effects of 1,3,4-oxadiazoline derivatives were tested against four bacterial strains, namely, *Enterococci*, *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella spp.*, and *Proteus spp.*, and the tow fungus, *Aspergillus niger* and *Candida albicans*. The antimicrobial activity was determined using the standard agar diffusion method [21]. Dimethyl sulfoxide acted as a controller, and the test was carried out at a concentration of 100 mg/mL and by adding 50 μL to each disk (i.e., 5 μg/disk) using

DMSO as a solvent. The fungi and bacteria were subcultured in agar and potato dextrose agar media. For antibacterial and antifungal activities, the inhibition zone was compared with the standard drug after incubation at 37°C and 25°C for 24 h and 72 h, respectively. The results obtained are presented in **TABLE 1**.

Results and Discussion

Chemical synthesis

The N-carbamoylhydrazones employed, in this study, were prepared via condensation reaction of semicarbazide hydrochloride **1** with the corresponding aldehydes or ketones **2a-s** in refluxing methanolic sodium acetate in presence of acetic acid affording semicarbazones **3a-s** with yields ranging 85-96%. The treatment of N-carbamoylhydrazones **3a-s** with refluxing excess acetic anhydride producing a new series of 3-acetyl-5-acetamido-1,3,4-oxadiazoline derivatives **4a-s** (**FIG. 1**) in good yields, after purification by recrystallization using ethanol or methanol. The purity of the compounds was checked by TLC and their elemental analysis, which matched within $\pm 0.3\%$ - 0.4% of the theoretical values.




FIG.1. Synthesis of 2,3-dihydro-1,3,4-oxadiazole derivatives 4a-s.

The plausible mechanism of the cyclization of N-carbamoylhydrazones **3a-s** to 3-acetyl-5-acetamido-2,3-dihydro-1,3,4-oxadiazolines **4a-s**. Where induced through the addition of acetic anhydride into imine bond producing intermediate 3', which tautomerized to new intermediate 3" followed with elimination of acetic acid molecule to furnish 1,3,4-oxadiazoline derivatives **4a-s** with substitution at amino group of the ring as shown in **FIG. 2** [22]. The formation of non-obtainable 5-amino-1,3,4-oxadiazolines **5a-s** dose not observed, further research in this reaction appears promising and necessary.




FIG.2. Suggested mechanism for formation of 1,3,4-oxadiazolines 4a-s

It is worth mentioning that a series of 2-acylamino-1,3,4-oxadiazoles 5 were directly synthesized by oxidation of 1,4-diacylthiosemicarbazides 6 with aqueous KIO_3 in two hours or by direct acylation of 2-amino-1,3,4-oxadiazoles 7 as shown in FIG.3.




FIG.3. Synthesis of 2-acylamino-1,3,4-oxadiazole derivatives 5.

Spectroscopic characterization

The structures of the newly synthesized compounds 4a-s characterized by IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and Mass spectra studies. The spectroscopic studies proved the successful acetic anhydride-promoted oxidative cyclization of N-carbamoylhydrazones 3a-s. In their IR spectra of 1,3,4-oxadiazolines 4a-s the characteristic peak for the amine NH_2 at $3400\text{-}3300\text{ cm}^{-1}$ and C=O at $1630\text{ cm}^{-1}\text{-}1650\text{ cm}^{-1}$ of the starting semicarbazones 3a-s completely disappeared from the IR spectra of the obtained products 4a-s. A new C=O stretching of two acetyl groups appeared at $1660\text{-}1670\text{ cm}^{-1}$, amide NH around 3250 cm^{-1} , C-O-C of ring at $1150\text{ cm}^{-1}\text{-}1170\text{ cm}^{-1}$, and C=N stretching of dihydro-oxadiazole ring appeared in the range of $1550\text{-}1615\text{ cm}^{-1}$. The second confirmation of the correct structure for compounds 4a-s, comes from their mass spectra were found in good agreement with the newly synthesized compounds.

The $^1\text{H-NMR}$ spectra provided clear evidence about the right structure of synthesized compounds 4a-s. The first evidence comes from the disappearance of the characteristic protons of the NH group at $9.0\text{ ppm}\text{-}10.0\text{ ppm}$ and carbamoyl NH_2 at $5.6\text{-}5.8\text{ ppm}$, in the $^1\text{H-NMR}$ spectra of starting compounds 3a-s. The disappearance of the NH protons was accompanied by the appearance of a new signal for amide NH at $10.9\text{-}11.5\text{ ppm}$ and two singlet signals at $2.3\text{-}2.5\text{ ppm}$ and these peaks were attributed to 2CH_3 protons of two acetyl groups indicating the formation of the N-substituted oxadiazoline ring. In compounds, 4a-i the O-CH-N proton was resonated in the range of $6.3\text{-}7.1\text{ ppm}$ instead of $8.3\text{-}8.9\text{ ppm}$ as shown in precursor hydrazones 3a-i.

The $^{13}\text{C-NMR}$ spectra provided an unambiguous confirmation about the formation of the N-acetyl-2,3-dihydro-1,3,4-oxadiazole ring. In synthesized compounds 4a-s there are a new peaks appeared for acetyl group carbons and this indeed are expected, because they are not part of starting hydrazones 3a-s. where the carbonyl (C=O) of the acetyl groups appeared as two peaks at $166.0, 167.0\text{ ppm}$ due to presence of two acetyl groups, and the other peaks appeared around $23.2/23.7, \text{ ppm}$ are assigned to be the peaks of the 2CH_3 of two acetyl groups. In the same spectra, two major new peaks appeared and both of them confirm the formation of the Nacetyl oxadiazoline ring. The first new and significant peak appeared at $88.0\text{-}92.0\text{ ppm}$ which assigned to the carbon-2 (O-C-N) of the 2,3-dihydrooxadiazole ring of compounds 4a-i and the other signal at $83.5\text{-}90.5\text{ ppm}$, is attributed to quaternary carbon of oxadiazoline ring of compounds 4j-s was of special significance in conforming the proposed structure. Which is similar to the reported values of quaternary carbons flanked by heteroatoms in oxadiazole rings [18,23]. The chemical shifts of two ring carbon atoms C-2 and C-5 were dependent on the substituents at the 2- and 5-positions of the 1,3,4-oxadiazoline ring.

Biological activity investigations

The activity of the synthetic compounds against the vulnerable bacteria *Enterococci*, *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella* spp., and *Proteus* spp., as well as two species of fungi, *Aspergillus niger* and *Candida albicans*, was assessed using the standard nutrient agar disc diffusion method [24,25]. One gram of each compound was dissolved in 10 ml of DMSO. Thus, 100 mg/ml of stock was obtained as a standard concentration of compounds. The compounds were examined at a concentration of 1 mg mL⁻¹ in a solution of Dimethyl Sulfoxide (DMSO), and all tests were implemented in triplicates and the average diameter of the inhibitory zone was measured in millimeters.

In comparison to well-known antibacterial and antifungal chemicals like tetracycline and fluconazole, the results showed that all of the tested compounds shown a significant amount of action against bacteria and fungi. NCCLS classifies inhibition zones for tetracycline and fluconazole as “highly active” (inhibition zone ≥ 19 mm), “moderately active” (inhibition zone 15 mm–18 mm), or “inactive” (inhibition zone ≤ 14 mm) [25]. The activity against both bacteria and fungus was moderately enhanced by the addition of the N-acetyl moiety (TABLE 1). Future medicinal chemists may use the results of the current work to develop and create molecules with a similar structure with greater biological efficacy.

Tab. 1. Antimicrobial screening results of the tested compounds 4a-s.

Diameter of the Inhibition Zone in mm*							
Cpd. No.	Antibacterial Activity			Antifungal Activity			
	<i>Enterococcus i</i>	<i>Escherichia coli</i>	<i>Staphyloaureus</i>	<i>Klebsiella spp</i>	<i>Proteus spp</i>	<i>Candida albicans</i>	<i>Aspergillus niger</i>
4a	18	16	18	16	18	16	19
4b	19	18	19	17	17	19	16
4c	18	16	17	15	16	18	16
4d	17	18	19	17	16	15	14
4e	16	19	16	19	15	19	13
4f	17	16	18	17	16	17	19
4g	19	18	17	19	16	18	16
4h	18	16	19	18	19	16	18
4i	16	19	16	19	16	19	17
4j	18	16	18	16	17	16	19
4k	16	17	17	15	16	16	18
4l	17	18	17	16	15	17	18
4m	19	15	17	18	16	18	16
4n	16	16	17	18	19	16	17
4o	17	19	16	19	16	17	19
4p	18	16	17	19	16	18	19
4q	18	15	15	17	16	18	16
4r	17	16	17	18	19	16	18
4s	17	19	16	19	18	19	18
Tet. ^a Flu. ^b	25	21	23	22	24	26	25
DMSO	--	--	--	--	--	--	--

Note: * Calculated as average of three values. ^aTetracycline, ^bFluconazole

Conclusion

New series of novel functionalized 1,3,4-oxadiazolines 4a-s were synthesized upon the treatment of carbamoylhydrazones of aldehydes 3a-i, ketones 3j-s with acetic anhydride under refluxing conditions and evaluated for their in vitro antibacterial, and antifungal activities. From the screening results, it found to possess various antimicrobial activities towards all the microorganisms tested. The results confirm that, the antimicrobial activity is strongly dependent on the nature of the substituents on oxadiazole ring and the presence of acetyl group at position-3 and acetamido group at position-2 of the ring enhance their biological activities. To better understand the chemical mechanism causing the activity seen, further research is needed to fully understand the remarkable

features of this novel family of antimicrobial compounds. A more thorough investigation is also necessary to identify new physicochemical and biological factors in order to better understand the relationship between structure and activity and to maximize the efficiency of this group of molecules.

Acknowledgements

All authors contributed equally to the conception and design of the study. The authors would like to thank Dr. Ahmed Abu Samahah, Biological Technology Department of Al-Aqsa University for Biological Assays.

References

1. Yang FF, Zhou JZ, Xu XL, et al. Discovery of 1, 3, 4-oxadiazole derivatives containing a bisamide moiety as a novel class of potential cardioprotective agents. *Eur J Med Chem.* 2022;239:114526.
2. AZ Abu-Zaied M, AM Nawwar G, H Swellem R, et al. Synthesis and screening of new 5-substituted-1, 3, 4-oxadiazole-2-thioglycosides as potent anticancer agents. *Pharmacol pharm.* 2012;3(2):254-61.
3. Othman AA, Kihel M, Amara S. 1, 3, 4-Oxadiazole, 1, 3, 4-thiadiazole and 1, 2, 4-triazole derivatives as potential antibacterial agents. *Arab J Chem.* 2019;12(7):1660-75.
4. Ahsan MJ. 1, 3, 4-Oxadiazole containing compounds as therapeutic targets for cancer therapy. *Mini Rev. Med. Chem.* 2022;22(1):164-97.
5. Luczynski, M., Kudelko, A. *Appl. Sci.* **2022**, 12(8), 3756-3775. doi.org/10.22034/- jcr.2022.341351.1170
6. Kalyankar TM, Kakade RB, Harshe PB. Oxadiazole: A Promising Class with Different Pharmacological Activity. *Asian J Res Chem.* 2012;5(8):1084-91.
7. Verma SK, Verma R, Kumar KS, et al. A key review on oxadiazole analogs as potential methicillin-resistant *Staphylococcus aureus* (MRSA) activity: Structure-activity relationship studies. *Eur j med chem.* 2021;219:113442.
8. Chaudhary T, Upadhyay PK. Recent advancement in synthesis and bioactivities of 1, 3, 4-oxadiazole. *Curr Org Synth.* 2023;20(6):663-77
9. De SS, Khambete MP, Degani MS. Oxadiazole scaffolds in anti-tuberculosis drug discovery. *Bioorg med chem lett.* 2019;29(16):1999-2007.
10. Lee SL, Cameron AM, Warkentin J. Thermolysis of Δ^3 -1, 3, 4-Oxadiazolin-2-ones. *Can J Chem.* 1972;50(14):2326-31.
11. Alcazar O, Hernandez LF, Nakayasu ES, et al. Parallel multi-omics in high-risk subjects for the identification of integrated biomarker signatures of type 1 diabetes. *Biomolecules.* 2021;11(3):383.
12. Yale HL, Losee K, Martins J, et al. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds 1, 2. *J Am Chem Soc.* 1953;75(8):1933-42.
13. Zhang J, Qiang G, Shen T, et al. Synthesis, characterization and bioactivities of the new 3-acetyl-2, 5-disubstituted-1, 3, 4-oxadiazolines. *IOP Publ.* 2019;612(2):022049.
14. Lodha BC. Decomposition of digested litter. *Biol plant litter decompos.* 1974;1:213-41
15. Joshi SD, More UA, Pansuriya K, et al. Synthesis and molecular modeling studies of novel pyrrole analogs as antimycobacterial agents. *J Saudi Chem Soc.* 2017;21(1):42-57.
16. Okimoto M, Chiba T. Electrochemical oxidation of ketone acylhydrazones and their hydrogen cyanide adducts in sodium cyanide-methanol. Transformation of ketones to nitriles. *J Org Chem.* 1990;55(3):1070-6.
17. Siddiqui N, Sonenberg N. Proposing a mechanism of action for ataluren. *Proc Natl Acad Sci.* 2016;113(44):12353-5.
18. Balouiri M, Sadiki M, Ibsouda SK. Methods for in vitro evaluating antimicrobial activity: A review *J Pharm Anal. NAT PROD RES.* 2016.
19. Morjan RY, El-Hallaq AF, Azarah JN, et al. Synthesis, docking and evaluation of novel fused pyrimidine compounds as possible lead compounds with antibacterial and antitumor activities. *J Mol Struct.* 2023;1288:135754.
20. Manika N, Chanotiya CS, Darokar M, et al. Compositional characters and antimicrobial potential of *Artemisia stricta* Edgew. f. *stricta* Pamp. essential oil. *Rec Nat Prod.* 2016;10(1):40.
21. Hamadi NB, Haouas A, Methamem M, et al. Synthesis of new pyrazolines and their biological evaluation as antimicrobial agents. *J Chem Res.* 2012;36(10):563-5.
22. Giacometti A, Cirioni O, Barchiesi F, et al. In vitro susceptibility tests for cationic peptides: comparison of broth microdilution methods for bacteria that grow aerobically. *Antimicrob agents chemother.* 2000;44(6):1694-6.
23. Manika, M., Chanotiya, C. S., Darokar, M., Singh, S., Bagchi, G. D. *Rec. Nat. Prod.* 2016, 10: 40-46.
24. CLSI, "Methods for dilution antimicrobial susceptibility tests for bacteria grow aerobically" Approved Standard M7-A4, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2005.

25. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th edition. Approved standard M07-A9, Clinical and Laboratory Standards Institute Wayne, PA, USA. 2012.